ACRF leads the way in digital innovation

World Cancer DayWednesday 4th February marks World Cancer Day and, in the next step towards putting an end to cancer, one of Australia’s leading cancer charities, the Australian Cancer Research Foundation (ACRF), will launch the world’s first charity-driven Top-Level Domain (TLD) .CancerResearch.

.CancerResearch is an internet domain enabling a new digital collective. It will be developed by the ACRF in collaboration with Australian cancer scientists and research centres, providing authoritative information, awareness movements, research news and important messages of hope for both Australian and global communities.

As the suite of .CancerResearch sites expands, international researchers, cancer sufferers, advocates and fundraisers will all have a powerful, unified voice on cancer research.

This effort towards ‘one’ voice will be highlighted in the Foundation’s introductory .CancerResearch awareness campaign, which can be seen at www.TheOne.CancerResearch.

TheOne.CancerResearch uses the latest in digital and social technology to provide an interactive experience for all supporters of cancer research, compiling their many thousands of faces into ‘The One’ entity that will enable new treatments and cures for cancer.

CEO of ACRF Professor Ian Brown said: “We have kick-started our launch with an incredible, community-based initiative – TheOne.CancerResearch. It has been developed through the support of M&C Saatchi and involves a powerful digital experience with the aim of mobilising our supporters in the fight against cancer.

“.CancerResearch is an internet domain with a collaborative vision. We have a long road ahead, but bringing the greatest minds and movements for cancer research together begins now.”

With the ACRF recently celebrating its 30th Anniversary, the launch of a new top-level domain marks a significant milestone for the Foundation. Since its inception, the ACRF has provided more than $100 million for cancer research, supporting major breakthroughs such as the early development of the cervical cancer vaccine.

For more information, please visit: www.theone.cancerresearch